tiprankstipranks
Acadia Pharmaceuticals price target lowered to $15 from $17 at Mizuho
The Fly

Acadia Pharmaceuticals price target lowered to $15 from $17 at Mizuho

Mizuho analyst Uy Ear lowered the firm’s price target on Acadia Pharmaceuticals to $15 from $17 and keeps a Neutral rating on the shares. The analyst reduced sales forecasts for Nuplazid ahead of the company’s expected late-February 2023 guidance. He beli;eves his prior Nuplazid sales estimates, particularly for 2023, were optimistic given the ongoing challenges in the Parkinson’s disease market and the Inflation Reduction Act price increase restriction.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ACAD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles